Abstract Book 2013.Indd
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Directory of Companies A
65 Directory of Companies A An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe 3B PHARMACEUTICALS GMBH Magnusstraße 11 12489 BERLIN DE 3M BELGIUM Canadastraat 11, Haven 1005 2070 ZWIJNDRECHT BE 3V-LSI Rubicondreef 18 3561 JC UTRECHT NL of Companies 4SC AG Am Klopferspitz 19a 82152 MARTINSRIED DE A & D INSTRUMENTS LTD Abingdon Science Park OX14 3YX ABINGDON GB ABBVIE DEUTSCHLAND GMBH & CO. KG Knollstrasse 67061 LUDWIGSHAFEN DE Directory ABCR GMBH Im Schlehert 10 76187 Karlsruhe, GERMANY Contact person: Dr. Ute Kiso Tel: +49 721 95061-0 - [email protected] www.abcr.de Gute Chemie. Welcome to abcr. With abcr, you have access to over 260,000 products from the organic, organometallic and inorganic specialty chemicals area. These can be conveniently ordered via our webshop www.abcr.de > Catalogue & Bulk business from grams to tons > Scale up & Commercial manufacturing from our own facility > Sourcing & Logistic management worldwide > Feasibility studies & Synthesis at the laboratory scale > Custom syntheses & Contract Manufacturing ABSORPTION SYSTEMS 440 Creamery Way Suite 300 PA 19341 EXTON US AC IMMUNE SA EPFL Innovation Park Building B 1015 LAUSANNE FR ACCELA CHEMBIO 9823 Pacific Heights Blvd # F 92121 SAN DIEGO US ACRAF S.P.A. Piazzale della Stazione 40 S. PALOMBA - POMEZIA IT ACROS ORGANICS Janssen Pharmaceuticalaan 3a 2440 GEEL BE ACS Journal of Medicinal Chemistry & ACS Medicinal Chemistry Letters Contact person: Janice E. Silverman, Acquisitions Editor Tel: +1 202-577-5975 [email protected] Journal of Medicinal Chemistry – pubs.acs.org/jmc ACS Medicinal Chemistry Letters – pubs.acs.org/acsmedchemlett In 2017 Journal of Medicinal Chemistry is celebrating 60 years of publishing the field’s best peer-reviewed research. -
Contents Page
Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9 -
Acacia Pharma Group
This document comprises a prospectus (the “Prospectus”) relating to Acacia Pharma Group plc (the “Company” or “Acacia Pharma”) prepared in accordance with the prospectus regulation rules (the “Prospectus Regulation Rules”) of the UK Financial Conduct Authority (the “FCA”) made pursuant to section 73A of the Financial Services and Markets Act 2000, as amended (“FSMA”). This Prospectus has been approved by the FCA as the competent authority under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has been filed with and made available to the public in accordance with Rule 3.2 of the Prospectus Regulation Rules. The FCA only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company or of the quality of the Ordinary Shares that are the subject of this Prospectus. Investors should make their own assessment as to the suitability of investing in the Ordinary Shares. In addition, this Prospectus has been drawn up as a simplified prospectus in accordance with Article 14 of the Prospectus Regulation. The Belgian Financial Services and Markets Authority (“Belgian FSMA”) was notified of the passporting of this Prospectus in accordance with Article 25 of the Prospectus Regulation. The Company and the Directors, whose names appear on page 39 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Company and the Directors, the information contained in this document is in accordance with the facts and this document makes no omission likely to affect its import. -
A Science and Innovation Audit Report for the Midlands Engine
A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report 01 November 2016 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Contents Midlands Engine SIA – the headlines ....................................................................................1 1. Introduction to the Midlands Engine SIA...........................................................................4 2. SIA ‘hypotheses’ and ‘framework’ ...................................................................................10 3. Regional science and innovation assets and excellence..............................................19 4. Innovation strengths and our growth priorities..............................................................30 5. Market and technology drivers of change.......................................................................53 6. Innovation networks and behaviours ..............................................................................59 7. Next Steps – unlocking our productivity potential.........................................................67 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Midlands Engine SIA – the headlines 1. In Autumn 2015 the UK Government announced regional Science and Innovation Audits (SIAs) to catalyse -
A Preclinical Evaluation of the Discriminative And
NP5101_proof ■ 12 June 2013 ■ 1/11 Neuropharmacology xxx (2013) 1e11 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm 1 56 2 A preclinical evaluation of the discriminative and reinforcing 57 3 58 4 properties of lisdexamfetamine in comparison to D-amfetamine, 59 5 fi 60 6 methylphenidate and moda nil 61 7 62 a,* a a a b 8 Q5 David J. Heal , Niki W. Buckley , Jane Gosden , Nigel Slater , Charles P. France , 63 9 David Hackett c 64 10 65 a 11 RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK 66 b University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA 12 c Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke RG24 8EP, Hampshire, UK 67 13 68 14 69 15 article info abstract 70 16 71 17 Article history: Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first 72 18 Received 12 December 2012 prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic 73 19 Received in revised form hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other 74 3 April 2013 20 stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and 75 Accepted 13 May 2013 21 modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing 76 effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)- 77 22 Keywords: cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. -
In the Flanker Task
Individual differences in uncertainty tolerance are not associated with cognitive control functions in the flanker task Philipp Alexander Schroeder1,3, David Dignath2, and Markus Janczyk3 1 Department of Psychiatry and Psychotherapy, University of Tübingen 2 Department of Psychology, University of Freiburg 3 Department of Psychology, University of Tübingen ACCEPTED FOR PUBLICATION IN EXPERIMENTAL PSYCHOLOGY (23 FEB 18) UNCERTAINTY TOLERANCE & COGNTIVE CONTROL 2 Short title Uncertainty tolerance & cognitive control Correspondence Dipl.-Psych. Philipp A. Schroeder Dept. of Psychiatry & Psychotherapy, University of Tübingen Calwerstr. 14 72076 Tübingen Mail: [email protected] Tel.: +49 7071 29 80815 Fax.: +49 7071 29 5904 Sponsors Work of MJ is supported by the Institutional Strategy of the University of Tübingen (Deutsche Forschungsgemeinschaft [German Research Foundation], ZUK 63). Work of DD is supported by a grant within the Priority Program, SPP 1772 (Deutsche Forschungsgemeinschaft [German Research Foundation], DI 2126/1-1). Acknowledgments The authors thank Lea Johannsen for help with pseudo-randomization procedure in Exp.2. Word count 4929 words Number of figures 5 Number of tables 1 URL to raw data publication https://osf.io/fmqu8/?view_only=398c1e5b4b4743f7af309a7ffca52660 UNCERTAINTY TOLERANCE & COGNTIVE CONTROL 3 Abstract Cognitive control refers to the ability to make correct decisions concurrent to distracting information, and to adapt to conflicting stimulus configurations, eventually promoting goal-directed behavior. Previous research has linked individual differences in cognitive control to psychopathological conditions such as anxiety. However, a link with uncertainty tolerance (UT) has not been tested so far, although both constructs describe cognitive and behavioral performance in ambiguous situations, thus they share some similarities. -
Evidence from the Eriksen Flanker Task and the Spatial Conflict Task
2007 • volume 3 • no 3 • 389-396 Advances in Cognitive Psychology Conditional accuracy in response interference tasks: Evidence from the Eriksen flanker task and the spatial conflict task John F. Stins1,2, J. C. Tinca Polderman1, Dorret I. Boomsma1, and Eco J. C. de Geus1 1 Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands 2 Research Institute MOVE, Faculty of Human Movement Sciences,VU University, Amsterdam, the Netherlands Received xx.xx.2007 Accepted xx.xx.2007 Keywords response interference, sequential analysis, accuracy, Simon task, flanker ABSTRACT CAFs revealed that in both tasks congruency and sequential trial effects on accuracy are found only Two well-known response interference tasks are in trials with fast responses (< 600 ms). Sequen- the Eriksen flanker task and the spatial conflict tial trial effects on accuracy were weaker for the task. The tasks are logically equivalent, and com- flanker task than for the spatial conflict task. In parable effects of current and previous stimu- very fast trials (< 400 ms) response activation by lus type (congruent or incongruent) have been distracting flankers led to below-chance perform- shown with regard to reaction time (RT). Here, ance in the flanker task, but response activation we investigated whether interference and se- by incongruent spatial location did not lead to quential trial effects also had comparable effects below-chance performance in the spatial conflict on accuracy. We specifically tested whether these task. The pattern of results hints at subtle dif- effects interacted with the speed of responding ferences in processing architecture between the using conditional accuracy functions (CAFs). The tasks. -
Haloperidol Impairs Learning and Error-Related Negativity in Humans
Haloperidol Impairs Learning and Error-related Negativity in Humans Patrick J. Zirnheld, Christine A. Carroll, Paul D. Kieffaber, Brian F. O’Donnell, Anantha Shekhar, and William P. Hetrick Abstract & Humans are able to monitor their actions for behavioral Performance Task, the Eriksen Flanker Task, and a learning- conflicts and performance errors. Growing evidence suggests dependent Time Estimation Task. Haloperidol significantly that the error-related negativity (ERN) of the event-related attenuated ERN amplitudes recorded during the flanker task, cortical brain potential (ERP) may index the functioning of impaired learning of time intervals, and tended to cause this response monitoring system and that the ERN may de- more errors of commission, compared to placebo, which pend on dopaminergic mechanisms. We examined the role did not significantly differ from diphenhydramine. Drugs of dopamine in ERN and behavioral indices of learning by had no significant effects on the stimulus-locked P1 and N2 administering either 3 mg of the dopamine antagonist (DA) ERPs or on behavioral response latencies, but tended to af- haloperidol (n = 17); 25 mg of diphenhydramine (n = 16), fect post-error reaction time (RT) latencies in opposite ways which has a similar CNS profile but without DA proper- (haloperidol decreased and diphenhydramine increased ties; or placebo (n = 18) in a randomized, double-blind RTs). These findings support the hypothesis that the DA manner to healthy volunteers. Three hours after drug ad- system is involved in learning and the generation of the ministration, participants performed a go/no-go Continuous ERN. & INTRODUCTION subjects need to have learned a representation of the Humans are able to monitor their actions for behavioral goal behavior for this negativity to be observed conflicts and performance errors, and then modify (Holroyd & Coles, 2002; Dehaene et al., 1994). -
Flanker Paradigm Contains Conflict and Distraction Factors with Distinct Neural Mechanisms: an ERP Analysis in a 2-1 Mapping Task
Cognitive Neurodynamics (2019) 13:341–356 https://doi.org/10.1007/s11571-019-09529-w (0123456789().,-volV)(0123456789().,-volV) RESEARCH ARTICLE Flanker paradigm contains conflict and distraction factors with distinct neural mechanisms: an ERP analysis in a 2-1 mapping task 1 1 1 2 Shu Zhou • Shenglan Xiong • Wenwen Cheng • You Wang Received: 1 March 2018 / Revised: 25 February 2019 / Accepted: 18 March 2019 / Published online: 22 March 2019 Ó Springer Nature B.V. 2019 Abstract Behavioral studies using the flanker 2-1 mapping task suggest that both stimulus and response conflicts contribute to flanker conflict effect. However, both are intertwined with distraction effect. Their underlying neural mechanisms remain unclear. We applied a perceptual flanker 2-1 mapping task to 24 healthy young adults, while the event-related potentials were recorded. The task included stimulus-incongruent (SI), response-incongruent (RI), congruent (CO) and neutral (NE) stimuli. Our reaction time data demonstrated conflict effect, distraction effect and their interaction. Furthermore, the conflict factor successively enhanced the frontal P2 (160–240 ms), the posterior N2pc (200–240 ms), the fronto-central and the right frontal N2b (240–420 ms), and the posterior N2c (320–420 ms). Only the frontal P2 was larger for RI than SI. The distraction factor increased the right N2pc and reduced the left parietal P3b (460–480 ms). Overall, our findings suggested that the flanker conflict involved an early attentional processing of task-relevant and distractive information, and a later processing of conflict evaluation and response inhibition. Keywords Cognitive control Á Flanker conflict Á Distraction Á 2-1 mapping Á Event-related potentials (ERP) Á Statistical parametric mapping (SPM) Introduction task (Simon and Rudell 1967), and Eriksen flanker task (Eriksen and Eriksen 1974). -
Running Head: NEURAL CORRELATES of ATTENTIONAL CONTROL THEORY 1
Running head: NEURAL CORRELATES OF ATTENTIONAL CONTROL THEORY 1 NEURAL CORRELATES OF ATTENTIONAL CONTROL THEORY IN HIGH TRAIT ANXIOUS INDIVIDUALS A THESIS SUBMITTED TO THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE MASTER OF ARTS IN CLINICAL PSYCHOLOGY BY RICHARD T. WARD DR. STEPHANIE SIMON-DACK – ADVISOR BALL STATE UNIVERSITY MUNCIE, INDIANA JULY 2017 NEURAL CORRELATES OF ATTENTIONAL CONTROL THEORY 2 Neural Correlates of Attentional Control Theory in High Trait Anxious Individuals Trait anxiety, as defined by Spielberger (1966), involves the experience of excessive worry, nervousness, and apprehension for a prolonged period of time. Individuals displaying maladaptive high levels of trait anxiety have demonstrated a variety of impairments across multiple cognitive domains including working memory. Attentional Control Theory provides an explanation as to how maladaptive high trait anxiety can impact working memory through the impairment of central executive functions (Eysenck & Derakshan, 2011), and a number of behavioral investigations have provided evidence in support of this theory (Eysenck, Paynea, & Derakshan., 2005; Derakshan & Eysenck, 2009; Ansari & Derakshan, 2010; Johnson, 2009; Ansari, Derakshan, & Richards, 2008; Murray & Jannell, 2003). However there is currently a lack in understanding of the underlying neural processes that give rise to Attentional Control Theory’s components. Therefore, the goal of the current study was to investigate the underlying neural correlates of the tenets of Attentional Control Theory. By understanding the neural mechanisms of maladaptive high trait anxiety, we gain a greater knowledge of the underlying processes of trait anxiety, and how it impacts the neural mechanisms involved with central executive functions. Trait Anxiety Spielberger (1966) defined trait anxiety as a personality trait, in which individuals high it are more prone to experience intense feelings of apprehension, tension, and excessive worry for a prolonged duration. -
BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY
Significant Capital Allowance Investment Opportunity BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease THE OPPORTUNITY Unique opportunity to acquire a new bio-science incubator facility let on a long lease to a major city council with significant capital allowances providing an attractive post tax return. Prominently located at Lower Parliament Street, Nottingham There are estimated £9,750,000 of available capital allowances to a adjacent to the existing Bio-City buildings within Nottingham’s purchaser which at a higher tax rate of 45% are worth £4,387,500 creative quarter. over a 5 year period. 150 years long-leasehold interest at a peppercorn rent from Nottingham City Council is to provide a loan to the purchaser of Nottingham City Council. £11,011,200 for a 5 years period at a fixed interest rate of 4.50% which equates to £495,484 interest per annum. No amortisation required during this period. Construction commenced in August 2015 on the new Biocity Science building over ground and 4 upper floors providing state of the art laboratory and office accommodation and extending to 52,475 sq ft Purchaser equity requirement of £6,748,800 which after interest NIA. Willmott Dixon is the appointed contractor. charges provides a net annual pre tax yield of 3.18%. To be let to Nottingham City Council for 30 years from completion of this transaction on a full repairing and insuring lease at an initial rent of Post tax annual yields are Year 1 - 7.54%, Year 2 - 6.86%, Year 3 - £714,000 per annum equating to £13.61 per sq ft. -
Economic Strategy Research Bureau
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham Trent Institutional Repository (IRep) Biotechnology, life sciences and skills in D2N2: A report for Learn Direct and the D2N2 Local Enterprise Partnership Will Rossiter, David J. Smith, Nikolas Pautz, Daniel McDonald-Junor Economic Strategy Research Bureau Nottingham Business School Nottingham Trent University July 2018 2018 Contents Executive Summary............................................................................................................................ 4 1 Introduction ................................................................................................................................ 6 1.1 Approach ................................................................................................................................. 7 2 What are life sciences and the biotech industry? ....................................................................... 9 2.1 Origins of the Biotechnology industry .................................................................................. 10 2.2 Features of the emerging UK biotechnology industry .......................................................... 13 2.3 The Bioincubator boom of the 2000-2008 ............................................................................ 14 3 Restructuring, Open Innovation and Outsourcing in the Pharmaceutical Industry ................. 17 4 The Decline in Laboratory Technician training ........................................................................